Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles

Showing results (441-450 of 501) with videos related to

Pageof 51
Sort By:
Plastic and Reconstructive Surgery|May 9, 2017
Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased RiskAnna Loch-Wilkinson, Kenneth J Beath, Robert John William Knight, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|April 4, 2006
Radon activity concentration--a Euromet and BIPM supplementary comparisonA Röttger, A Honig, V Schmidt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patientsNadege Bercovici, Nacilla Haicheur, Severine Massicard, et al.
Cancer Epidemiology|May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control studySimon Cheah, Adrian J Lowe, Nina Afshar, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memoryClaude-Henry Volmar, Hasib Salah-Uddin, Karolina J Janczura, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Internal Medicine Journal|March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma AustraliaShirlene Sim, Anna Kalff, Gina Tuch, et al.
Oncoimmunology|September 26, 2015
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomibPaul J Neeson, Andy K Hsu, Yin R Chen, et al.
Expert Review of Hematology|September 5, 2023
Modifiable lifestyle risk factors and survival after diagnosis with multiple myelomaSimon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Pageof 51

Showing results (441-450 of 501) with videos related to

Sort By:
Pageof 51
Plastic and Reconstructive Surgery|May 9, 2017
Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased RiskAnna Loch-Wilkinson, Kenneth J Beath, Robert John William Knight, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|April 4, 2006
Radon activity concentration--a Euromet and BIPM supplementary comparisonA Röttger, A Honig, V Schmidt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patientsNadege Bercovici, Nacilla Haicheur, Severine Massicard, et al.
Cancer Epidemiology|May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control studySimon Cheah, Adrian J Lowe, Nina Afshar, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memoryClaude-Henry Volmar, Hasib Salah-Uddin, Karolina J Janczura, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Internal Medicine Journal|March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma AustraliaShirlene Sim, Anna Kalff, Gina Tuch, et al.
Oncoimmunology|September 26, 2015
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomibPaul J Neeson, Andy K Hsu, Yin R Chen, et al.
Expert Review of Hematology|September 5, 2023
Modifiable lifestyle risk factors and survival after diagnosis with multiple myelomaSimon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Pageof 51